Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;37(6):1107-1124.
doi: 10.1016/j.hoc.2023.05.017. Epub 2023 Jun 23.

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Ibrahim N Muhsen  1 , LaQuisa C Hill  1 , Carlos A Ramos  2
Affiliations
Review

Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas

Ibrahim N Muhsen et al. Hematol Oncol Clin North Am. 2023 Dec.

Erratum in

  • Erratum.
    [No authors listed] [No authors listed] Hematol Oncol Clin North Am. 2024 Feb;38(1):xv. doi: 10.1016/j.hoc.2023.11.001. Hematol Oncol Clin North Am. 2024. PMID: 37980074 No abstract available.

Abstract

The authors review the current use of chimeric antigen receptor (CAR)-transduced T cells (CAR-T) in Hodgkin lymphoma (HL) and T-cell lymphomas (TCL) and discuss the data on CD30-targeting CAR-T cells, which seem to be safe and effective in HL. In addition, the authors examine the use of CAR-T cells targeting CD30, CD5, or CD7 in TCL, while highlighting the unique challenges of their use in this subset of lymphomas. Furthermore, the authors present future directions and ongoing trials investigating the use of CAR-T cells in TCL and HL.

Keywords: CD30; CD5; CD7; Chimeric antigen receptor T cells; Hodgkin lymphoma; T-cell non-Hodgkin lymphoma.

PubMed Disclaimer

Conflict of interest statement

L.C.H. has consulted for March Biosciences, is a member of Speakers Bureau for Kite/Gilead, and served on advisory board for Incyte. C.A.R. has participated in advisory boards for Novartis, Genentech and CRISPR Therapeutics, and has received research funding from Athenex and Tessa Therapeutics. I.N.M. declares no conflict of interest.

Figures

Figure 1:
Figure 1:
A summary of the major CAR-T cell targets in Hodgkin and T-cell lymphomas. Adapted and modified with permission from: Leung WK, Ayanambakkam A, Heslop HE, Hill LC. Beyond CD19 CAR-T cells in lymphoma. Curr Opin Immunol. 2022 Feb; 74:46–52.
Figure 2:
Figure 2:
Different potential strategies of targeting CD30 using CAR-T cells are shown: (A) CD30.CARTs, (B) CD30.CARTs co-expressing CCR4 (CCL17 receptor), or (C) administering it along with immune checkpoint inhibitors (ICI). CCL17 is one of the chemokines secreted by HRS that is thought to attract immunosuppressive effector cells, such as regulatory T cells, to the tumor microenvironment. Expressing CCR4 in CAR-T cells takes advantage of an ordinarily immune inhibitory mechanism. (Figure created with BioRender.com)
See this image and copyright information in PMC

References

    1. Ansell SM, Radford J, Connors JM, et al. ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma. N Engl J Med. 2022. Jul 28;387(4):310–320. - PubMed
    1. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566. 50. - PMC - PubMed
    1. Moskowitz CH, Nademanee A, Masszi T, et al. ; AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862. - PubMed
    1. Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin’s lymphoma cells in the presence of soluble CD30. Cancer Res. 1998. Mar 15;58(6):1116–9. - PubMed
    1. Savoldo B, Rooney CM, Di Stasi A, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007. Oct 1;110(7):2620–30. - PMC - PubMed

Publication types